Patents Assigned to TheraVida, Inc.
-
Patent number: 11779569Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.Type: GrantFiled: November 1, 2021Date of Patent: October 10, 2023Assignee: TheraVida, Inc.Inventor: Benjamin F. McGraw, III
-
Patent number: 11185533Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.Type: GrantFiled: February 21, 2020Date of Patent: November 30, 2021Assignee: THERAVIDA, INC.Inventor: Benjamin F. McGraw, III
-
Patent number: 10786457Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: GrantFiled: April 10, 2018Date of Patent: September 29, 2020Assignee: THERAVIDA, INC.Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
-
Patent number: 10610519Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.Type: GrantFiled: May 3, 2019Date of Patent: April 7, 2020Assignee: THERAVIDA, INC.Inventor: Benjamin F. McGraw, III
-
Patent number: 10328057Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.Type: GrantFiled: March 10, 2017Date of Patent: June 25, 2019Assignee: THERAVIDA, INC.Inventor: Benjamin F. McGraw, III
-
Patent number: 9968556Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: GrantFiled: July 6, 2016Date of Patent: May 15, 2018Assignee: TheraVida, Inc.Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
-
Patent number: 9744157Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 26, 2015Date of Patent: August 29, 2017Assignee: TheraVida, Inc.Inventors: Mehdi Paborji, Wendy Jade Limayo Hernandez, Kenneth L. Duchin, Roger S. Flugel
-
Patent number: 9415013Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: GrantFiled: April 1, 2011Date of Patent: August 16, 2016Assignee: TheraVida, Inc.Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
-
Patent number: 9132124Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 21, 2012Date of Patent: September 15, 2015Assignee: THERAVIDA, INC.Inventors: Mehdi Paborji, Wendy Jade Limayo Hernandez, Kenneth L. Duchin, Roger S. Flugel
-
Patent number: 8940763Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 9, 2012Date of Patent: January 27, 2015Assignee: TheraVida, Inc.Inventors: Mehdi Paborji, Wendy Jade Limayo Hernandez, Kenneth L. Duchin, Roger S. Flugel
-
Publication number: 20140194454Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 11, 2014Publication date: July 10, 2014Applicant: TheraVida, Inc.Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
-
Publication number: 20140105976Abstract: Disclosed herein are pharmaceutical compositions comprising at least one minitablet, where the minitablet comprises a core, comprising pilocarpine, or a pharmaceutically acceptable salt thereof; and a coating layer comprising a coating polymer.Type: ApplicationFiled: October 11, 2013Publication date: April 17, 2014Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Robert V. TUOHY, Stephen P. LEVINE, Dana E. MOSESON, Nicolas D. KIRKLAND
-
Publication number: 20130296392Abstract: Disclosed herein are methods of treating overactive bladder in a patient, the method comprising identifying a patient in need thereof; and administering to the patient a composition comprising tolterodine, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, wherein after the administration Cmax for tolterodine is between 1.0-8.0 ng/mL.Type: ApplicationFiled: May 1, 2013Publication date: November 7, 2013Applicant: TheraVida, Inc.Inventors: Mehdi PABORJI, Roger S. FLUGEL, Kenneth L. DUCHIN
-
Patent number: 8470864Abstract: Disclosed herein are pharmaceutical compositions comprising oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.Type: GrantFiled: February 22, 2010Date of Patent: June 25, 2013Assignee: Theravida, Inc.Inventor: Mehdi Paborji
-
Publication number: 20120289563Abstract: Disclosed are pharmaceutical compositions comprising a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Wendy Jade Limayo HERNANDEZ, Kenneth L. DUCHIN, Roger S. FLUGEL
-
Publication number: 20120289564Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
-
Publication number: 20120289529Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
-
Publication number: 20120289560Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
-
Publication number: 20120289543Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Wendy Jade Limayo HERNANDEZ, Kenneth L. DUCHIN, Roger S. FLUGEL
-
Publication number: 20120289567Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 21, 2012Publication date: November 15, 2012Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL